2019 Future of Thromboembolism R&D Pipeline Drugs and Companies- Analysis of Global Thromboembolism Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Thromboembolism treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Thromboembolism pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Thromboembolism pipeline companies from advancing their products into Phase 3 or Phase 4.
Thromboembolism Report Description
The H1 2019 pipeline review report on Thromboembolism pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Thromboembolism pipeline compounds.
The Thromboembolism pipeline guide presents information on all active drugs currently being developed for Thromboembolism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Thromboembolism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Thromboembolism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Thromboembolism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Thromboembolism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Thromboembolism pipeline report includes
REASONS TO BUY
Thromboembolism Report Description
The H1 2019 pipeline review report on Thromboembolism pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Thromboembolism pipeline compounds.
The Thromboembolism pipeline guide presents information on all active drugs currently being developed for Thromboembolism. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Thromboembolism pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Thromboembolism drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Thromboembolism product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Thromboembolism pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Thromboembolism pipeline report includes
- An overview of Thromboembolism disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Thromboembolism pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Thromboembolism pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Thromboembolism pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL THROMBOEMBOLISM PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Thromboembolism Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Thromboembolism pipeline, H1- 2019
3.5 Mechanism of Action wise Thromboembolism Pipeline Candidates
4. ARROWHEAD PHARMACEUTICALS, INC THROMBOEMBOLISM PIPELINE DETAILS
4.1 Arrowhead Pharmaceuticals, Inc Business Profile
4.2 Arrowhead Pharmaceuticals, Inc Thromboembolism Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. BAYER AG THROMBOEMBOLISM PIPELINE DETAILS
5.1 Bayer AG Business Profile
5.2 Bayer AG Thromboembolism Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. THROMBOEMBOLISM PIPELINE DETAILS
6.1 China Biologic Products Holdings, Inc. Business Profile
6.2 China Biologic Products Holdings, Inc. Thromboembolism Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. DAIICHI SANKYO COMPANY, LIMITED THROMBOEMBOLISM PIPELINE DETAILS
7.1 Daiichi Sankyo Company, Limited Business Profile
7.2 Daiichi Sankyo Company, Limited Thromboembolism Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. IONIS PHARMACEUTICALS INC THROMBOEMBOLISM PIPELINE DETAILS
8.1 Ionis Pharmaceuticals Inc Business Profile
8.2 Ionis Pharmaceuticals Inc Thromboembolism Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. JANSSEN PHARMACEUTICALS, INC. THROMBOEMBOLISM PIPELINE DETAILS
9.1 Janssen Pharmaceuticals, Inc. Business Profile
9.2 Janssen Pharmaceuticals, Inc. Thromboembolism Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. LEE'S PHARMACEUTICAL HOLDINGS THROMBOEMBOLISM PIPELINE DETAILS
10.1 Lee's Pharmaceutical Holdings Business Profile
10.2 Lee's Pharmaceutical Holdings Thromboembolism Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. PFIZER INC THROMBOEMBOLISM PIPELINE DETAILS
11.1 Pfizer Inc Business Profile
11.2 Pfizer Inc Thromboembolism Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. PROTHIX BV THROMBOEMBOLISM PIPELINE DETAILS
12.1 Prothix BV Business Profile
12.2 Prothix BV Thromboembolism Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. QUERCEGEN PHARMACEUTICALS LLC THROMBOEMBOLISM PIPELINE DETAILS
13.1 Quercegen Pharmaceuticals LLC Business Profile
13.2 Quercegen Pharmaceuticals LLC Thromboembolism Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. ROCHE HOLDING AG THROMBOEMBOLISM PIPELINE DETAILS
14.1 Roche Holding AG Business Profile
14.2 Roche Holding AG Thromboembolism Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. SHANDONG TAIBANG BIOLOGICAL PRODUCTS CO.LTD. THROMBOEMBOLISM PIPELINE DETAILS
15.1 Shandong Taibang Biological Products Co.Ltd. Business Profile
15.2 Shandong Taibang Biological Products Co.Ltd. Thromboembolism Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. TEARX LTD. THROMBOEMBOLISM PIPELINE DETAILS
16.1 TeaRx Ltd. Business Profile
16.2 TeaRx Ltd. Thromboembolism Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. VERSEON CORP THROMBOEMBOLISM PIPELINE DETAILS
17.1 Verseon Corp Business Profile
17.2 Verseon Corp Thromboembolism Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. LATEST THROMBOEMBOLISM DRUG PIPELINE DEVELOPMENTS, 2019
19. APPENDIX
19.1 About Us
19.2 Sources and Methodology
19.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL THROMBOEMBOLISM PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Thromboembolism Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Thromboembolism pipeline, H1- 2019
3.5 Mechanism of Action wise Thromboembolism Pipeline Candidates
4. ARROWHEAD PHARMACEUTICALS, INC THROMBOEMBOLISM PIPELINE DETAILS
4.1 Arrowhead Pharmaceuticals, Inc Business Profile
4.2 Arrowhead Pharmaceuticals, Inc Thromboembolism Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. BAYER AG THROMBOEMBOLISM PIPELINE DETAILS
5.1 Bayer AG Business Profile
5.2 Bayer AG Thromboembolism Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. THROMBOEMBOLISM PIPELINE DETAILS
6.1 China Biologic Products Holdings, Inc. Business Profile
6.2 China Biologic Products Holdings, Inc. Thromboembolism Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. DAIICHI SANKYO COMPANY, LIMITED THROMBOEMBOLISM PIPELINE DETAILS
7.1 Daiichi Sankyo Company, Limited Business Profile
7.2 Daiichi Sankyo Company, Limited Thromboembolism Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. IONIS PHARMACEUTICALS INC THROMBOEMBOLISM PIPELINE DETAILS
8.1 Ionis Pharmaceuticals Inc Business Profile
8.2 Ionis Pharmaceuticals Inc Thromboembolism Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. JANSSEN PHARMACEUTICALS, INC. THROMBOEMBOLISM PIPELINE DETAILS
9.1 Janssen Pharmaceuticals, Inc. Business Profile
9.2 Janssen Pharmaceuticals, Inc. Thromboembolism Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. LEE'S PHARMACEUTICAL HOLDINGS THROMBOEMBOLISM PIPELINE DETAILS
10.1 Lee's Pharmaceutical Holdings Business Profile
10.2 Lee's Pharmaceutical Holdings Thromboembolism Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. PFIZER INC THROMBOEMBOLISM PIPELINE DETAILS
11.1 Pfizer Inc Business Profile
11.2 Pfizer Inc Thromboembolism Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. PROTHIX BV THROMBOEMBOLISM PIPELINE DETAILS
12.1 Prothix BV Business Profile
12.2 Prothix BV Thromboembolism Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. QUERCEGEN PHARMACEUTICALS LLC THROMBOEMBOLISM PIPELINE DETAILS
13.1 Quercegen Pharmaceuticals LLC Business Profile
13.2 Quercegen Pharmaceuticals LLC Thromboembolism Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. ROCHE HOLDING AG THROMBOEMBOLISM PIPELINE DETAILS
14.1 Roche Holding AG Business Profile
14.2 Roche Holding AG Thromboembolism Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. SHANDONG TAIBANG BIOLOGICAL PRODUCTS CO.LTD. THROMBOEMBOLISM PIPELINE DETAILS
15.1 Shandong Taibang Biological Products Co.Ltd. Business Profile
15.2 Shandong Taibang Biological Products Co.Ltd. Thromboembolism Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. TEARX LTD. THROMBOEMBOLISM PIPELINE DETAILS
16.1 TeaRx Ltd. Business Profile
16.2 TeaRx Ltd. Thromboembolism Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. VERSEON CORP THROMBOEMBOLISM PIPELINE DETAILS
17.1 Verseon Corp Business Profile
17.2 Verseon Corp Thromboembolism Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. LATEST THROMBOEMBOLISM DRUG PIPELINE DEVELOPMENTS, 2019
19. APPENDIX
19.1 About Us
19.2 Sources and Methodology
19.3 Contact Information
